Evidence map›Paper›PMID 33924890›Full record

ReviewInternational journal of molecular sciences2021

The Implication of Reticulons (RTNs) in Neurodegenerative Diseases: From Molecular Mechanisms to Potential Diagnostic and Therapeutic Approaches.

Agnieszka Kulczyńska-Przybik, Piotr Mroczko, Maciej Dulewicz, Barbara Mroczko

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.0field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. ER discontinuities are common inbioRxiv : the preprint server for biology · 2026
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Agnieszka Kulczyńska-PrzybikDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.ORCID 0000-0002-9889-3585
Piotr MroczkoDepartment of Criminal Law and Criminology, Faculty of Law, University of Bialystok, 15-213 Bialystok, Poland.
Maciej DulewiczDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.ORCID 0000-0002-7149-017X
Barbara MroczkoDepartment of Neurodegeneration Diagnostics, Medical University of Bialystok, 15-269 Bialystok, Poland.ORCID 0000-0002-4075-8479
Medical University of Białystok · PLUniversity of Białystok · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Reticulons (RTNs) are crucial regulatory factors in the central nervous system (CNS) as well as immune system and play pleiotropic functions. In CNS, RTNs are transmembrane proteins mediating neuroanatomical plasticity and functional recovery after central nervous system injury or diseases. Moreover, RTNs, particularly RTN4 and RTN3, are involved in neurodegeneration and neuroinflammation processes. The crucial role of RTNs in the development of several neurodegenerative diseases, including Alzheimer's disease (AD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or other neurological conditions such as brain injury or spinal cord injury, has attracted scientific interest. Reticulons, particularly RTN-4A (Nogo-A), could provide both an understanding of early pathogenesis of neurodegenerative disorders and be potential therapeutic targets which may offer effective treatment or inhibit disease progression. This review focuses on the molecular mechanisms and functions of RTNs and their potential usefulness in clinical practice as a diagnostic tool or therapeutic strategy.

Indexed as

AnimalsCarrier ProteinsHumansMembrane ProteinsMolecular Targeted TherapyNerve Tissue ProteinsNeurodegenerative DiseasesNogo ProteinsCarrier ProteinsMembrane ProteinsNerve Tissue ProteinsNogo ProteinsRTN3 protein, humanAlzheimer’s diseaseamyotrophic lateral sclerosismultiple sclerosisneurodegenerative diseasesnogo proteinsreticulons

Identifiers

PMID33924890
PMCPMC8125174
OpenAlexW3159958144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.